Share
Dr. Di Hong
Nona Biosciences, a global biotechnology company delivering integrated solutions from "Idea to IND" (I to ITM), has appointed Dr. Di Hong as Chief Executive Officer (CEO).
Based in Shanghai, Dr. Hong will report directly to Dr. Jingsong Wang, Chairman of Nona Biosciences, and lead the company into its next phase of innovation and global expansion.
This appointment marks a pivotal step for Nona in advancing antibody discovery and development. Leveraging its proprietary Harbour Mice® technology platform, the company has expanded capabilities with HCAb PLUSTM, a next-generation system integrating bispecific and multispecific antibodies, antibody-drug conjugates (ADCs), cell therapies, RNA-enabled therapeutics, and artificial intelligence (AI). These innovations are designed to reshape the drug discovery landscape and foster a global collaborative ecosystem.
In his new role, Dr. Hong will drive technology innovation, strengthen Nona’s service system, integrate AI and external investment, and evolve the business into a "Service Plus" ecosystem-powered platform. His leadership is expected to enhance strategic agility and position Nona Biosciences for long-term leadership in the global biopharmaceutical industry.
Dr. Hong brings over 20 years of experience spanning science, operations, and strategy. Most recently, as CEO of Gaoyue Group, he built a national life science network and established a "Lab-to-Market" ecosystem. He has also held senior roles at Hua Medicine, Bioduro-Sundia, Amgen, Eli Lilly, and Roche, combining global and local expertise across biopharma, CRO, and investment.
Dr. Hong holds a Doctor of Business Administration from Université Nice Sophia Antipolis and Master’s and Bachelor’s degrees in Chemistry from Zhejiang University, positioning him to lead Nona Biosciences toward transformative growth and innovation.
